These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 24022996)

  • 1. Structure-guided design affirms inhibitors of hepatitis C virus p7 as a viable class of antivirals targeting virion release.
    Foster TL; Thompson GS; Kalverda AP; Kankanala J; Bentham M; Wetherill LF; Thompson J; Barker AM; Clarke D; Noerenberg M; Pearson AR; Rowlands DJ; Homans SW; Harris M; Foster R; Griffin S
    Hepatology; 2014 Feb; 59(2):408-22. PubMed ID: 24022996
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Computational Docking Study of p7 Ion Channel from HCV Genotype 3 and Genotype 4 and Its Interaction with Natural Compounds.
    Mathew S; Fatima K; Fatmi MQ; Archunan G; Ilyas M; Begum N; Azhar E; Damanhouri G; Qadri I
    PLoS One; 2015; 10(6):e0126510. PubMed ID: 26030803
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genotype-dependent sensitivity of hepatitis C virus to inhibitors of the p7 ion channel.
    Griffin S; Stgelais C; Owsianka AM; Patel AH; Rowlands D; Harris M
    Hepatology; 2008 Dec; 48(6):1779-90. PubMed ID: 18828153
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatitis C virus-specific directly acting antiviral drugs.
    Delang L; Neyts J; Vliegen I; Abrignani S; Neddermann P; De Francesco R
    Curr Top Microbiol Immunol; 2013; 369():289-320. PubMed ID: 23463206
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular design, synthesis and biological evaluation of cage compound-based inhibitors of hepatitis C virus p7 ion channels.
    Shiryaev VA; Radchenko EV; Palyulin VA; Zefirov NS; Bormotov NI; Serova OA; Shishkina LN; Baimuratov MR; Bormasheva KM; Gruzd YA; Ivleva EA; Leonova MV; Lukashenko AV; Osipov DV; Osyanin VA; Reznikov AN; Shadrikova VA; Sibiryakova AE; Tkachenko IM; Klimochkin YN
    Eur J Med Chem; 2018 Oct; 158():214-235. PubMed ID: 30218908
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Resistance mutations define specific antiviral effects for inhibitors of the hepatitis C virus p7 ion channel.
    Foster TL; Verow M; Wozniak AL; Bentham MJ; Thompson J; Atkins E; Weinman SA; Fishwick C; Foster R; Harris M; Griffin S
    Hepatology; 2011 Jul; 54(1):79-90. PubMed ID: 21520195
    [TBL] [Abstract][Full Text] [Related]  

  • 7. "Too little, too late?" Will inhibitors of the hepatitis C virus p7 ion channel ever be used in the clinic?
    Griffin S
    Future Med Chem; 2014; 6(17):1893-907. PubMed ID: 25495983
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Small molecule inhibitors of the hepatitis C virus-encoded NS5A protein.
    Belda O; Targett-Adams P
    Virus Res; 2012 Dec; 170(1-2):1-14. PubMed ID: 23009750
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rationally derived inhibitors of hepatitis C virus (HCV) p7 channel activity reveal prospect for bimodal antiviral therapy.
    Shaw J; Gosain R; Kalita MM; Foster TL; Kankanala J; Mahato DR; Abas S; King BJ; Scott C; Brown E; Bentham MJ; Wetherill L; Bloy A; Samson A; Harris M; Mankouri J; Rowlands DJ; Macdonald A; Tarr AW; Fischer WB; Foster R; Griffin S
    Elife; 2020 Nov; 9():. PubMed ID: 33169665
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibitor Development against p7 Channel in Hepatitis C Virus.
    Wei S; Hu X; Du L; Zhao L; Xue H; Liu C; Chou JJ; Zhong J; Tong Y; Wang S; OuYang B
    Molecules; 2021 Mar; 26(5):. PubMed ID: 33802584
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Significance of hepatitis C virus baseline polymorphism during the antiviral therapy].
    Tornai I
    Orv Hetil; 2015 May; 156(21):849-54. PubMed ID: 26038992
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dehydrojuncusol, a Natural Phenanthrene Compound Extracted from
    Sahuc ME; Sahli R; Rivière C; Pène V; Lavie M; Vandeputte A; Brodin P; Rosenberg AR; Dubuisson J; Ksouri R; Rouillé Y; Sahpaz S; Séron K
    J Virol; 2019 May; 93(10):. PubMed ID: 30842319
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatitis C virus resistance to protease inhibitors.
    Halfon P; Locarnini S
    J Hepatol; 2011 Jul; 55(1):192-206. PubMed ID: 21284949
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Future treatment of chronic hepatitis C with direct acting antivirals: is resistance important?
    Halfon P; Sarrazin C
    Liver Int; 2012 Feb; 32 Suppl 1():79-87. PubMed ID: 22212577
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of novel small molecule inhibitors against the NS3/4A protease of hepatitis C virus genotype 4a.
    El-Sayed SM; Ali MAM; El-Gendy BEM; Dandash SS; Issac Y; Saad R; Azab MM; Mohamed MR
    Curr Pharm Des; 2018; 24(37):4484-4491. PubMed ID: 30501598
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antiviral effects of amantadine and iminosugar derivatives against hepatitis C virus.
    Steinmann E; Whitfield T; Kallis S; Dwek RA; Zitzmann N; Pietschmann T; Bartenschlager R
    Hepatology; 2007 Aug; 46(2):330-8. PubMed ID: 17599777
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery and development of VX-950, a novel, covalent, and reversible inhibitor of hepatitis C virus NS3.4A serine protease.
    Lin C; Kwong AD; Perni RB
    Infect Disord Drug Targets; 2006 Mar; 6(1):3-16. PubMed ID: 16787300
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The combination of alisporivir plus an NS5A inhibitor provides additive to synergistic anti-hepatitis C virus activity without detectable cross-resistance.
    Chatterji U; Garcia-Rivera JA; Baugh J; Gawlik K; Wong KA; Zhong W; Brass CA; Naoumov NV; Gallay PA
    Antimicrob Agents Chemother; 2014 Jun; 58(6):3327-34. PubMed ID: 24687498
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of HCV p7 as a therapeutic target.
    Griffin S
    Curr Opin Investig Drugs; 2010 Feb; 11(2):175-81. PubMed ID: 20112167
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intracellular proton conductance of the hepatitis C virus p7 protein and its contribution to infectious virus production.
    Wozniak AL; Griffin S; Rowlands D; Harris M; Yi M; Lemon SM; Weinman SA
    PLoS Pathog; 2010 Sep; 6(9):e1001087. PubMed ID: 20824094
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.